M
Malcolm F. G. Stevens
Researcher at University of Nottingham
Publications - 316
Citations - 13044
Malcolm F. G. Stevens is an academic researcher from University of Nottingham. The author has contributed to research in topics: Temozolomide & Benzothiazole. The author has an hindex of 57, co-authored 315 publications receiving 12291 citations. Previous affiliations of Malcolm F. G. Stevens include Keele University & Hauptman-Woodward Medical Research Institute.
Papers
More filters
Journal ArticleDOI
G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.
Carlo Leonetti,Marco Scarsella,Giuseppe Riggio,Angela Maria Rizzo,Erica Salvati,Maurizio D'Incalci,Lidia Staszewsky,Roberta Frapolli,Malcolm F. G. Stevens,Antonella Stoppacciaro,Marcella Mottolese,Barbara Antoniani,Eric Gilson,Gabriella Zupi,Annamaria Biroccio +14 more
TL;DR: The data show that RHPS4 has a good pharmacodynamic profile and in combination therapy produces a strong antitumoral activity, identifying this drug as promising agent for clinical development.
Journal ArticleDOI
Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
Jennifer C. Cookson,Fangping Dai,Victoria Smith,Robert A. Heald,Charles A. Laughton,Malcolm F. G. Stevens,Angelika M. Burger +6 more
TL;DR: In combination studies, paclitaxel (Taxol), doxorubicin (Adriamycin), and the experimental therapeutic agent 17-(allylamino)-17-demethoxygeldanamycin, which inhibits the 90-kDa heat shock protein, conferred enhanced sensitivity inRHPS4 treated MCF-7 cells, whereas the DNA-interactive temozolomide and cisplatin antagonized the action of RHPS4.
Journal Article
In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles
Chee-Onn Leong,Marie Suggitt,David J. Swaine,Michael C. Bibby,Malcolm F. G. Stevens,Tracey D. Bradshaw +5 more
TL;DR: The effects of DNA adduct formation on cellular DNA integrity and progression through cell cycle and whether a relevant pharmacodynamic end point may be exploited to probe the clinical mechanism of action of Phortress and predict tumor response are investigated.
Journal ArticleDOI
Elucidation of thioredoxin as a molecular target for antitumor quinols.
Tracey D. Bradshaw,Charles S. Matthews,Jennifer C. Cookson,Eng-Hui Chew,Manish B. Shah,Kevin Bailey,Anne Monks,Erik Harris,Andrew D. Westwell,Geoffrey Wells,Charles A. Laughton,Malcolm F. G. Stevens +11 more
TL;DR: Results are consistent with a mechanism of action of novel antitumor quinols involving inhibition of the small redox protein thioredoxin.
Journal ArticleDOI
Structural studies on bioactive compounds. 40.(1) Synthesis and biological properties of fluoro-, methoxyl-, and amino-substituted 3-phenyl-4H-1-benzopyran-4-ones and a comparison of their antitumor activities with the activities of related 2-phenylbenzothiazoles.
David Vasselin,Andrew D. Westwell,Charles S. Matthews,Tracey D. Bradshaw,Malcolm F. G. Stevens +4 more
TL;DR: Significant potentiation of growth inhibitory activity was observed when MDA-MB-468 cells were co-incubated with TBDD, a powerful inducer of cytochrome P450 (CYP)-1A1 activity, suggesting that isoflavone derivatives can act as substrates for CYP 1A1 bioactivation.